Skip to main content
. 2023 May 21;228(6):734–741. doi: 10.1093/infdis/jiad163

Figure 1.

Figure 1.

Cytokine-secreting cells after recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rS) stimulation, assessed by enzyme-linked immunosorbent spot assay (ELISpot). Cells secreting interferon gamma (IFN-γ; A), tumor necrosis factor alpha (TNF-α; B), IFN-γ and TNF-α (C), or interleukin 5 (IL-5; D) after SARS-CoV-2 rS stimulation were detected by ELISpot. Geometric mean count (GMC) of cells per million peripheral blood mononuclear cells (PBMCs) secreting the requisite cytokine is plotted with 95% confidence intervals (CIs). Geometric mean fold rise (GMFR) in cytokine-secreting cells relative to day 0 (preimmunization) is indicated above the bars along with 95% CIs. Group A: placebo (day 0/7, n = 31; day 28, n = 29). Group B: 2-dose 5 µg rS + 50 µg Matrix-M adjuvant (n = 32, n = 31). Group C: 1-dose 5 µg rS + 50 µg Matrix-M adjuvant (n = 28, n = 25). Group D: 2-dose 25 µg rS + 50 µg Matrix-M adjuvant (n = 33, n = 30). Group E: 1-dose 25 µg rS + 50 µg Matrix-M adjuvant (n = 31, n = 28).